Introduction
Multiple myeloma is estimated to affect 19 900 individuals in the United States in 2007, and in spite of the recent improvements in therapy appears to be incurable. 1 Highdose therapy and autologous peripheral blood SCT has been utilized for treatment of myeloma for over two decades and has been the standard of care for patients able to undergo the procedure. Several randomized clinical trials have confirmed the survival advantage for autologous SCT (ASCT) as compared to conventional chemotherapy which was mostly alkylator based, and large population-based studies also support this conclusion. 2, 3 Subsequent trials failed to demonstrate any survival advantage for an early ASCT following initial therapy of newly diagnosed disease as compared to delayed ASCT performed at the time of relapse from initial therapy. 4, 5 However, based on the improvement in quality of life indices based on time without any therapy, the trend has been to transplant patients early in the course of their disease. Typically, ASCT has been preceded by 4-6 months of initial therapy for disease burden reduction, followed by stem cell collection and high-dose therapy. While alkylating agents, such as melphalan, have been traditionally avoided in the pretransplant period due to concerns regarding its effect on stem cell collection, there have been no studies demonstrating an advantage for any of the initial therapies in terms of transplant outcome. On the contrary, review of transplant data have consistently demonstrated a lack of effect of the initial therapy on post transplant outcome with patients refractory to initial therapy garnering as much benefit from high-dose therapy (ASCT) as those responding to therapy. [6] [7] [8] [9] However, in the past few years several novel, highly effective treatment regimens became available that have been used for initial therapy of the patient with newly diagnosed myeloma. [10] [11] [12] [13] [14] [15] [16] It is not clear if induction therapy with thalidomide or lenalidomide with their higher response rates has any direct impact on the outcome following transplant in patients undergoing ASCT. To address this question, we examined the outcome of patients seen at our institution who underwent ASCT following initial therapy with different regimens.
Patients and methods
A total of 472 patients with multiple myeloma, who underwent stem cell collection and ASCT between April 1995 and February 2007 at Mayo Clinic, Rochester were included in this study. We only included patients who received early transplantation, defined as ASCT within 12 months of the initial diagnosis of myeloma. Patients receiving vincristine, adriamycin and dexamethasone (VAD), dexamethasone as a single agent (Dex), thalidomide plus dexamethasone (Thal-Dex) or lenalidomide plus dexamethasone (Len-Dex) were considered for this study. Patients who received more than one treatment regimen either due to a lack of response to initial therapy or toxicity were excluded from the study. Patients in whom thalidomide was added after lack of response to dexamethasone for 1-2 cycles were included in the study, and analysis was done with and without this group. Data from patients undergoing SCT is captured prospectively into a database which is continuously updated. Complete follow-up was available for all the patients. All patients had provided written informed consent for use of their medical records. Approval by the Mayo Foundation Institutional Review Board was obtained in accordance with federal regulations and the Declaration of Helsinki.
More than a third of the patients (165 patients, 35%) had their initial therapy with dexamethasone alone given in a pulsed-dose fashion at 40 mg per day on days 1-4, 9-12 and 17-20 of a 28-day treatment cycle. A total of 156 patients (33%) had induction therapy with dexamethasone in combination with thalidomide, with the thalidomide either added initially or after the first cycle because of lack of response to dexamethasone alone. Of the 156 patients in the Thal-Dex group, 24 (15%) had the thalidomide added later for suboptimal response to dexamethasone. The dexamethasone was generally given at 40 mg per day on days 1-4, 9-12 and 17-20. In the combination therapy, thalidomide was given at varying doses of 100-400 mg per day as tolerated. Nearly a quarter of patients (116; 24.6%) initially received infusional chemotherapy with VAD chemotherapy for four cycles. The dexamethasone was administered as originally described at 40 mg per day on days 1-4, 9-12 and 17-20 for all four treatment cycles. 17 Thirty-five patients (7.4%) received lenalidomide (25 mg per day for 21 days with 7 days off) with dexamethasone either given in a pulsed-dose fashion as with thalidomide or 40 mg weekly. The choice of initial therapy depended on clinical trials available at the time of diagnosis, but outside of a trial, patients were typically induced with dexamethasone or VAD.
After the completion of the induction therapy, stem cells were collected using G-CSF priming alone in 219 patients (46.3%). G-CSF was administered s.c. (10 mg/kg) daily until the completion of peripheral blood stem cell collection with aphereses beginning on the fifth day after starting G-CSF. The remaining 253 (53.7%) patients had stem cells collected after administration of CY 1.5 g/m 2 per day for 2 consecutive days, followed by GM-CSF or G-CSF at 5 mg/kg starting on day 3 and continuing through the period of granulocytopenia. Apheresis was performed once the total WBC count exceeded 500 per ml. Prior to 1997, the target for the apheresis procedure was 5 Bone marrow plasma cell labeling index (PCLI), cytogenetics, b2-microglobulin (b2M) and other laboratory variables were assessed pretransplantation. Labeling index, a measure of the cell kinetics is determined using a slidebased immunofluorescence method on BM samples, as previously described and is considered high when X1%.
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Response to therapy was defined according to the European Bone Marrow Transplantation Registry criteria. 19 Overall survival was defined as the time from transplantation or from the date of initial diagnosis of myeloma to the date of death or last follow-up, as the case may be. The w 2 and Fisher's exact tests were used to compare differences among the patient groups for nominal variables and the nonparametric tests Mann-Whitney U-test or Kruskal-Wallis test were used for continuous variables. Kaplan-Meier analysis was used for analyzing overall and progression-free survival and differences between survival curves were tested for statistical significance using the two-tailed log-rank test. 20 Multivariate analysis was performed using the Cox's Proportional Hazards Model. 21 
Results
A total of 472 patients were included in the study, and the baseline characteristics are given in Table 1 . The majority of patients undergoing ASCT before 2001 had received VAD induction ( Figure 1 ). The patients receiving VAD were younger as compared to those receiving dexamethasone alone, and the remaining two groups were comparable. A higher proportion of patients in the Dex group only as compared to the others had disease which was relapsing after initial therapy or primary refractory disease at the time of transplant reflecting a lower response rate to Dex as compared to other regimens. As expected markers of disease activity such as BM plasmacytosis, b2M, serum monoclonal protein concentration and presence of circulating plasma cells at the time of transplant, all tended to be highest in the dexamethasone group and lowest in those receiving lenalidomide and dexamethasone, consistent with the known superior response rates of immunomodulatory drugs-containing induction regimens. The depth of response at the time of ASCT could not be determined for all patients and hence not compared across the groups. Presence of risk factors, such as cytogenetic abnormalities, was comparable among the groups. More patients in the VAD group had stem cells collected with CY and growth factors as compared to other groups, reflecting an earlier institutional protocol for collecting stem cells. Use of CY mobilization has been previously shown to have no impact on the transplant outcome. 22 For the more recent transplants, we have been using CY only in patients with disease activity as indicated by the presence of circulating plasma cells detected by fluorescence microscopy. A higher proportion of patients in the VAD group received melphalan and TBI as conditioning treatment, again reflecting the earlier period of transplant in this group.
Analysis of engraftment kinetics demonstrated delayed platelet and neutrophil engraftment in the VAD group as compared to others, likely a reflection of increased proportion of patients in the VAD group receiving melphalan TBI for conditioning. 23 There was no significant difference in the treatment-related mortality among these patient groups. The overall response rates were similar in the four groups and there were more complete responses in the VAD group as compared to those receiving Thal-Dex or Len-Dex for initial therapy ( Figure 2 ). The estimated freedom from progression at 2 years from ASCT was 51.2±4.8%, 51.2±4.3%, 40.9±4.7% and 54.4 ± 17.4% for the VAD, Dex, Thal-Dex and Len-Dex groups, respectively. The results were identical when repeat analysis was done excluding patients with poor response to Dex, who had thalidomide added to their regimen. The median overall survival from ASCT was 62 months for VAD, 69.6 months for Dex and did not reach Thal-Dex and Len-Dex groups, P ¼ 0.2 ( Figure 3 ). The estimated survival at 2 years from ASCT was 78.8 ± 3.8 months, 80.1 ± 3.3 months, 84±3.3 months and 96.6±3.4 months, respectively, for the VAD, Dex, Thal-Dex and Len-Dex. The median (95% CI) overall survival from diagnosis was 70.2 months for VAD, 74 months for Dex and did not reach Thal-Dex and Len-Dex groups, P ¼ 0.3 ( Figure 4) . In a multivariate model examining factors predicting for progression, only high PCLI (X1%), presence of abnormal cytogenetics and failure to obtain a complete response significantly influenced the risk of relapse. 
Discussion
There has been a paradigm shift in the initial therapy of multiple myeloma during the past few years with the introduction of novel agents such as thalidomide, bortezomib and lenalidomide. [10] [11] [12] [13] [14] [15] [16] Until the introduction of the new drugs, patients eligible for high-dose therapy were usually treated with dexamethasone-based regimens such as VAD or single agent dexamethasone for 4-6 cycles before proceeding to ASCT. Alkylator-based regimens were used rarely in these patients due to concerns that they could impair stem cell collection. 24 Treatment of patients with these regimens for 4-6 cycles typically resulted in response rates of 50-60% with only a small proportion of patients achieving a complete response prior to ASCT. [25] [26] [27] Previous studies have not demonstrated any long-term impact of the initial therapy on ASCT outcome in terms of TTP or survival, but these studies did not use novel agents in the induction phase. [6] [7] [8] [9] The response status before the transplant had minimal impact on the eventual outcome of ASCT, with patients refractory to initial therapy obtaining as much benefit from the procedure as those who were responding to the pretransplant therapy. Incorporation of the new drugs into the initial treatment of myeloma has resulted in increased response rates including higher CR rates than those seen with the previous steroid-based regimens. 10, 11 The combination of thalidomide and dexamethasone has been shown to be superior to dexamethasone alone in patients with newly diagnosed myeloma in terms of response rates at 4 months and TTP. In a phase III trial in patients with newly diagnosed myeloma, the response rate after four cycles of therapy with Thal-Dex was significantly higher than with dexamethasone alone (63 vs 41%) and the CR rate was 4% with the combination as compared to 0% with dexamethasone. 10 In another multicenter trial with a similar design, TTP was significantly longer with Thal-Dex vs placebo-Dex, median TTP of 17.4 vs 6.4 months, respectively. 28 In a retrospective, matched The survival curves were compared using log-rank test.
case-control analysis of 200 patients who were treated with Thal-Dex (n ¼ 100) or VAD (n ¼ 100) on two consecutive studies from 1996 to 2003 by Cavo et al., 29 Thal-Dex resulted in a significantly higher partial response rate (76 vs 52%) and more profound reduction in serum M-protein levels. Similarly, use of bortezomib in the setting of newly diagnosed myeloma has been associated with very high response rates, without compromising the ability to collect stem cells for ASCT.
14 Most recently, use of lenalidomide and dexamethasone has led to high response rates in patients with newly diagnosed myeloma and, especially when combined with lower dose weekly dexamethasone, has been associated with improvement in survival. 15, 16 Given the significantly higher response rates associated with the newer regimens, it is not clear that initial therapy with these regimens has any impact on the outcome after transplant. In the current study, we did not observe any differences between the groups in terms of the overall response to transplant, though patients receiving VAD pretransplant appeared to have higher complete response rates. Given that complete responses may only be confirmed later in the post transplant period, this may be biased to some extent by the shorter post transplant followup among those receiving Thal-Dex or Len-Dex regimens. In a phase III trial that randomized patients with newly diagnosed myeloma to receive Thal-Dex or VAD prior to SCT, 24.7 and 7.3% of patients, respectively, were in very good partial remission (VGPR) prior to PBSC collection. 30 At 6 months post transplant, the benefit of Thal-Dex over VAD was not seen and the VGPR rates were comparable (44.4% in the Thal-Dex arm and 41.7% in the VAD arm). No significant differences were observed with respect to the median TTP among the four groups of patients. There was a trend toward shorter TTP among those treated with thalidomide dexamethasone as compared to other regimens, a difference that was not statistically significant. Since the study set consisted of a group of patients who had suboptimal response to initial therapy with dexamethasone and went on to have thalidomide added to their treatment regimen, we also examined the results by excluding these patients. The results were identical even with the exclusion of the patients with poor response to dexamethasone. Another potential explanation, which cannot be verified in this retrospective study, is the possibility that many of the patients with an excellent response to thalidomide and dexamethasone, VGPR or better, may have opted for a delayed transplant approach thus enriching the transplant cohort with patients achieving less than a VGPR. However, a similar effect was not seen in the lenalidomide group and would argue against this explanation. This question will need to be addressed in the long-term analysis of randomized clinical trials that compared thalidomide with dexamethasone or VAD. No differences were seen in the overall survival from diagnosis or post transplant in the Thal-Dex group as compared to other groups. Examination of early survival after diagnosis (1 and 2 year estimates of survival) appears to favor the Len-Dex arm, but interpretation of this data is limited by the small number of patients in this group and the relatively short follow-up. However, any potential survival benefit seen in the face of similar TTP may be related to increasing availability of newer agents for salvage therapy post relapse. One-year survivals in excess of 90% were recently reported from a randomized trial comparing lenalidomide with two different doses of dexamethasone. 15 However, this effect is thought to be related to a reduction in early deaths, which should not impact the current study since we have only included patients reaching transplant.
The results of the current study should be used in a limited manner to guide the initial therapy of myeloma. The study has the inherent limitation of selecting for patients who survived the initial period after diagnosis. This is an important consideration since early results with the novel therapies suggest that these drugs used early may have a beneficial impact on early mortality seen in patients with myeloma, which typically have exceeded 10% in the first year in most randomized trials. However, it is clear from our study that for patients receiving SCT, the initial therapy does not appear to have any long-term impact on the outcome from their SCT at least for Thal-Dex as compared to the previously used regimens. Long-term results from the current phase III trials evaluating bortezomib or lenalidomide-based regimens as initial therapy will clarify the potential impact of these drugs. It is quite likely that the brief duration of therapy prior to SCT with any of these drugs may not have a long-term impact in terms of progression-free survival after transplantation. The lack of impact of initial therapy on the outcome of the SCT should be reassuring to the patient who has already been initiated on therapy with one of these regimens, who is facing the question of SCT. Achievement of a complete response is one of the strongest predictors of TTP after ASCT. 31, 32 While long-term results with the new regimens such as Len-Dex appear to result in CR rates comparable to that of ASCT, the CR rates after four cycles of treatment, where a majority of patients go on to receive high-dose therapy is under 10% and far below the CR rates seen with transplant. 11 So it is quite conceivable that initial demonstrating the median overall survival from diagnosis among the groups of patients receiving different initial therapies for their disease. The survival curves were compared using log-rank test.
therapy may not impact the results of ASCT unless the CR rates with these agents, in the short term, exceed that typically seen with ASCT as highlighted by the phase III trial that compared Thal-Dex to VAD. In conclusion, the higher response rates seen with thalidomide and lenalidomide in the initial treatment of myeloma does not translate into longer relapse-free survival among patients receiving SCT within the first year of diagnosis.
